Purpose: To assess the feasibility of acquiring vessel size imaging (VSI) metrics using ferumoxytol injections and stock pulse sequences in a multicenter Phase I trial of a novel therapy in patients with advanced metastatic disease. Methods: Scans were acquired before, immediately after, and 48 h after injection, at screening and after 2 weeks of treatment. DR 2 , DR Ã 2 , vessel density (Q), and relative vascular volume fractions (VVF) were estimated in both normal tissue and tumor, and compared with model-derived theoretical and experimental estimates based on preclinical murine xenograft data. Results: R 2 and R Ã 2 relaxation rates were still significantly elevated in tumors and liver 48 h after ferumoxytol injection; liver values returned to baseline by week 2. Q was relatively insensitive to changes in DR 
INTRODUCTION
Quantitative MRI-based techniques are increasingly used in early-phase oncology trials to monitor changes in tumor microvasculature associated with novel antiangiogenic therapies. Dynamic contrast-enhanced MRI (DCE-MRI), the most common method used to assess anti-angiogenic therapies (1) , requires rapid image acquisition during the bolus injection of a gadolinium chelate, providing a mixed measure of tumor perfusion and permeability and relative model-based measures of extravascular extracellular and blood plasma volumes (2) . DCE-MRI has proven useful for evaluating drugs where the mechanism-of-action includes changes in vascular permeability, such as those targeting vascular endothelial growth factor (VEGF) (3) . However, for novel antiangiogenic drugs that do not target VEGF and have different predicted mechanisms of action, an imaging method sensitive to structural changes in the microvasculature independent of changes in vascular permeability would be valuable. DCE-MRI-derived parameters may remain unchanged in the case of microvessel diameter increase and vessel density decrease. In addition, eliminating the high temporal resolution imaging requirement would be beneficial, especially when assessing relatively small tumors and metastases or those subject to physiologic motion such as within the abdomen.
Vessel size imaging (VSI) is an alternative approach to assessing microvasculature noninvasively (4) that exploits the differential dependence of R 2 (1/T 2 ) and R Ã 2
(1/T Ã 2 ) relaxation rates on the physical dimensions of microscopic susceptibility distortions. Due to the sensitivity of T 2 -MRI to water diffusion, DR 2 depends on the vessel diameter, while DR Ã 2 does not (at clinical field strengths and sufficient susceptibility shift). By measuring changes in these relaxation rates with an intravascular susceptibility contrast agent, estimates for mean microvessel caliber or vessel size index (5), vessel density related index (Q) (6) , and relative blood volume (vascular volume fraction, VVF) can be derived noninvasively. As initially described (4), these microstructural estimates are derived by imaging before injection of an intravascular magnetic susceptibility contrast agent and postinjection at steady-state concentration. The ability to perform steady-state imaging avoids the inevitable tradeoff between high speed and limited resolution/coverage seen with DCE-MRI and allows acquisition of higher spatial resolution data.
Several groups have demonstrated agreement between VSI-based measurements of tumor mean vessel caliber and microvessel density determined by invasive measurements (4, 7, 8) in xenograft models, validating the VSI methodology. Preclinical studies have also demonstrated that VSI metrics are sensitive to the effects of anti-VEGF and anti-angiogenic therapies (8) (9) (10) (11) (12) , providing confidence that this approach may be useful for assessing these targeted therapies clinically. The use of VSI in humans has been limited by the restricted availability of a suitable intravascular contrast agent; several iron-based contrast agents have been discontinued in the United States, leaving no FDA-approved contrast agent available for clinical MRI. Nevertheless, measurements have been made in the brain by means of dynamic imaging with standard low molecular weight gadolinium-based contrast agents (9) and customized pulse sequences able to concurrently measure changes in both T 2 and T Ã 2 (13) (14) (15) (16) (17) , or dual-bolus injections (18) . However, the dynamic imaging approach to VSI suffers from greater temporal sampling rate requirements compared with DCE-MRI.
Ferumoxytol (Feraheme TM , AMAG Pharma Inc., Lexington, MA) is a USPIO (ultrasmall superparamagnetic iron oxide) nanoparticle approved to treat iron deficiency anemia in adult patients with chronic kidney disease. Ferumoxytol has been used preclinically as an intravascular contrast agent, demonstrating sufficient sensitivity to monitor perturbations caused by antiangiogenic therapies (19) (20) (21) (22) . To date, quantitative clinical MRI with ferumoxytol has focused primarily on evaluating perfusion/permeability in normal brain tissue and central nervous system lesions (23) (24) (25) (26) (27) (28) (29) (30) (31) . Making measurements outside of the brain is more difficult because of the effects of respiratory and cardiac motion and susceptibility artifacts, which are especially problematic for echo-planar imaging approaches. Performing VSI in nonbrain lesions is of great importance from a drug development perspective, because the majority of patients in Phase I oncology trials have advanced metastatic disease with lesions in the chest and abdomen. The liver is a common metastatic site in this patient population, which could be problematic for USPIO-based imaging because Kupffer cells in the surrounding normal liver take up iron oxide nanoparticles; in fact, the liver is the main elimination route of exogenous iron. Persistent relaxivity changes due to the presence of iron oxide nanoparticles in the normal liver aid in the visualization of hepatic lesions, but may limit the ability to make repeat measures of quantitative VSI parameters either before treatment for repeatability studies, or over relatively short time frames (e.g., < 48 h) after initiating investigational treatments.
We evaluated the feasibility of acquiring VSI data using ferumoxytol in advanced-stage cancer patients with solid tumors in the body (32) , as part of a multicenter Phase I clinical trial of MINT1526A, a novel humanized monoclonal antibody against the a 5 b 1 integrin, an angiogenesis regulator. The primary objective of the trial was to assess safety and tolerability of MINT1526A alone and in combination with the anti-VEGF antibody bevacizumab. The aims of the VSI substudy were to design an imaging protocol using standard product pulse sequences on 1.5T MR scanners to provide measures of VSI indices; evaluate interpatient variability of vascular imaging metrics in both normal tissues and solid tumors; gain insights into the time course of contrast changes and the effect on VSI indices (particularly in liver lesions); and assess translatability by comparing preclinical and clinical VSI measures in both normal and tumor tissue. Finally, we also report on the safety profile of using ferumoxytol as an iron-oxide contrast agent in a Phase I patient cohort.
METHODS

Patient Population
Scanning was conducted in 13 patients with advancedstage solid tumors who were screened for or enrolled in dose-expansion cohorts of a Phase I clinical trial of MINT1526A. To be included in the imaging component of the trial, patients had to have a lesion of greater than 3 cm in the longest dimension in the liver, or 2 cm in other metastatic sites. Exclusion criteria were: known hypersensitivity to ferumoxytol or any of its components, current or recent (within past 3 months) administration of ferumoxytol or similar iron substitute, evidence of iron overload (including but not limited to known hemochromatosis, chronic hemolysis, or chronic blood transfusions), requirement for diagnostic MRI for disease monitoring and/or clinical management [e.g., due to known intolerability to computed tomography (CT) contrast agent], and conventional contraindications to MRI.
Two scans were acquired during the trial screening period, before the start of study drug. The first scan included a ferumoxytol injection, while the second scan ($48 h after the first scan) evaluated delayed effects of the prior ferumoxytol injection. Two additional scans, again with and without ferumoxytol injection and 48 h apart, were acquired after 2 weeks of study treatment (day 15 scans). Only limited on-treatment data is included here, as the focus of this manuscript is on the VSI implementation. All protocols were approved by the local Institutional Review Boards (IRB) where imaging was performed, and informed consent (including risks of ferumoxytol administration known at the time of the study) was obtained from all subjects.
Clinical Imaging Protocols
Clinical imaging protocols were implemented on two Siemens (Symphony, Espree) and one GE Signa 1.5 Tesla (T) MR scanners at three different imaging centers, using stock pulse sequences. Standard spine and torso phasedarray coils were used for signal reception, positioned to provide coverage of the target lesion(s) previously identified on diagnostic CT scans. All images were acquired in the transverse plane. A dual-echo multislice turbo spinecho (TSE) T 2 -weighted sequence (pulse repetition time (TR) 2600 ms, echo times (TE) 6 and 96 ms, echo train length 15) was used to derive maps of the estimated transverse relaxation rate, R 2 . R for both sequences were selected to maintain acquisition times within 15-to 20-s breath-holds to reduce motion artifacts.
To acquire 15-20 6-mm trans-axial slices, two to five breath-holds were required for each sequence. Data for R 2 and R Ã 2 maps were acquired both before and again starting 5 min after ferumoxytol injection. A 3 mg Fe/kg dose of ferumoxytol diluted 1:1 with saline was injected at 2 mL/ s using a power injector, followed by a saline flush. This dose, less than half of the full therapeutic dose, was chosen to be within the lower range of literature reported ferumoxytol doses (33, 34) to facilitate repeat studies. Ferumoxytol was injected during the first scan before study drug administration, and during the third scan, after 2 weeks of treatment. Patients were monitored for 60 min postinjection for any signs of possible anaphylactic reaction. Preinjection diffusion-weighted images (b ¼ 0, 200, 800 s/mm 2 for each of the 3 principal magnet axes, TR $3000 ms, TE $95 ms, eight averages, free-breathing) were also acquired, and used to calculate apparent diffusion coefficient (ADC) maps using monoexponential curve fitting. Additional imaging included anatomical scans (fast imaging with steady-state precession, FISP/FIESTA), T 1 -weighted and multi-flip angle T 1 -mapping scans. The total scan time was approximately 30 min.
Clinical Image Analysis
Multiecho data were fitted to monoexponential models to derive voxel-wise R 2 and R Ã 2 maps using MRVision software (MRVision Co., Redwood City, CA) at each imaging timepoint. Images were then spatially registered across timepoints using manual rigid body translations, to visually best match the target lesion(s). This procedure primarily corrects for slight variations in diaphragm position from scan to scan. Difference maps (DR 2 and DR Ã 2 ) were derived, which are proportional to microvascular and total blood volume, respectively. Maps of the vessel density related index (6) 
2/3 , were also generated. These three metrics were selected as they are among the simplest (and, therefore, likely the most robust) VSI-related metrics. Measurements were made in renal cortex, liver, muscle (typically in the muscle mass close to the vertebral column), and blood pool (generally descending aorta), if these regions were available within the scan field of view (FOV) for each patient. One to three target lesions were also evaluated per patient.
For each measurement, regions of interest (ROIs) were defined manually across several slices, avoiding any areas with obvious image artifacts due to motion or field inhomogeneity. Lesion ROI selection was guided by diffusion-weighted images and ADC maps; lesions or areas of lesions with relatively low ADC values (usually < $1.2 Â 10 À3 mm 2 /s) were preferentially selected. To simplify the analysis and remove potential errors due to multiple registration steps, DR Ã 2 , DR 2 , and Q parameters were also calculated from the median R 2 and R Ã 2 values within whole-lesion ROIs, and compared with registered image-derived values. Repeatability of these measurements was assessed by comparing screening and day 15 data in renal cortex, assuming normal tissues are essentially unaffected by treatment.
Relationship of R Ã 2tissue and Blood Ferumoxytol Concentration
When deriving relative blood volumes from steady-state susceptibility contrast data with an intravascular contrast agent, a fundamental assumption is that changes in R Ã 2tissue are linearly related to the tissue concentration of the contrast agent. This has been shown in preclinical models (5,23); Bjornerud et al (23) additionally showed that change in blood (R Ã 2blood ) is quadratically related to contrast agent concentration in a pig model with another USPIO agent, Clariscan TM . Using ferumoxytol, similar relationships were shown in human gray and white matter and the sagittal sinus (24) .
With only a single dose level of ferumoxytol in our protocol and no direct measures of contrast agent concentration, these described relationships could not be directly evaluated in our study. However, we were able to observe these relationships to some extent. The correlation between the square root of DR2 Ã blood and the blood concentration of Fe was first confirmed; the concentration was calculated as the injected dose of Fe divided by the total blood volume estimated using the Nalder Method (35) (6) . We evaluated these relationships in our data by examining both DR 2tissue and Q as a function of R Ã 2tissue in tumor and normal renal cortex, both in voxel-based and whole-ROI measurements.
Preclinical Imaging
Four athymic nude mice bearing human tumor xenografts of colorectal origin (HM-7) were imaged 10 days after inoculation. Tumor volumes, measured by caliper at the time of imaging, were 150-250 mm 3 . All animal procedures were approved by the Association for Assessment and Accreditation of Laboratory Animal Careaccredited Genentech review board.
VSI-MRI was performed on a 4.7T Varian Unity Inova MRI system with a 20-mm two-loop surface coil. Eight coronal, 1-mm-thick slices were acquired with a 25.6 Â 25.6 mm FOV and 64 Â 64 (ADC, T 2 ) or 128 Â 128 (T Ã 2 ) matrix. A multislice, diffusion-weighted fast spinecho imaging sequence was used to obtain ADC measurements (6 b-values from 82-1129 s/mm 2 , TR 3 s, echo train length 4, two averages, d 3.3 ms, D30 ms). R 2 and M 0 maps were acquired using a multislice, single-echo spin-echo imaging sequence (TE 5, 26, 47, 68 ms, TR 3 s, and one average) and R Ã 2 maps were acquired using a multiecho, multislice gradient echo sequence (TE 5, 10, 15, 20, 25, 30, 35, 40 ms, TR 345 ms, and four averages) before and 3 min postinjection of ferumoxytol (6 mg Fe/ kg by means of tail-vein catheter). The higher Fe/kg dose used in the murine model was selected to match the Fe/ kg dose used in previous preclinical experiments of ferumoxtyol and other iron-oxide based agents.
VSI MRI parameters were calculated voxel-by-voxel in the viable tumor tissue using the pre-and postcontrast R 2 and R Ã 2 maps and ADC maps in a multispectral approach (36, 37) . Muscle ROIs were drawn manually on the neighboring quadriceps muscle, also present in the imaging FOV. Imaging was conducted at a single session, without the administration of any study drug.
Estimation of Relative Vascular Volume Fraction
Vascular volume fraction (VVF) was calculated from measured DR Ã 2 values as previously described (5,6) using the following equation:
Because it was not possible to measure the susceptibility difference (Dv) in patients as part of the clinical trial, the ratio of VVF in tumor to VVF in normal tissue (muscle) was calculated, which simplifies to the ratio of DR Ã 2 in tumor to DR Ã 2 in muscle for each subject. The same ratio was also calculated using mouse data, and summary ratios were compared with the relative measures in humans. Assuming the same intravascular iron oxide agent is used, a scaling factor was needed to compare values across species (5) 
Data and Statistical Analysis
Data are presented as mean 6 standard deviation (SD). Correlations were evaluated in R (38) with a significance level of P < 0.05. A paired t-test assuming equal variance was used for comparisons between individual patient data at multiple timepoints.
RESULTS
Clinical Data: Image Analysis
Nine patients with metastatic disease (four colorectal cancer, two carcinoid, ovarian, osteosarcoma, and bladder cancer) completed the full imaging protocol and provided evaluable data. An additional four patients received ferumoxytol and participated in one or two scans during the screening period, but were either screen failures for the trial because of nonimaging eligibility criteria, or withdrew early. A total of 17 lesions (11 liver, 2 peritoneal, 2 lung, mesenteric, and renal) were suitable for analysis. No adverse events related to ferumoxytol injection were reported. Representative histograms from one patient (Fig. 1 ) show a marked increase in R 2 immediately following ferumoxytol injection in all tissues. By 48 h postinjection, R 2 had returned to baseline in the renal cortex and partially recovered in the lesion and normal liver.
The time course of R 2 and R Ã 2 changes in muscle, liver, renal cortex, and blood pool are summarized as mean ( 6 SD) in Figure 2 . Measurements in each tissue were possible in most, but not all patients, because of the required placement of the imaging FOV relative to tumor. Also, R 2 could not be measured in the blood in the aorta due to the spin-echo sequence used. Postinjection, the mean increase in R 2 was 121% 6 58% and 79% 6 41% in liver and renal cortex, respectively, which returned to 61% 6 18% and 42% 6 41% above baseline by 48 h. R Ã 2 increased by 612% 6 304% and 568% 6 253% in liver and renal cortex, and returned to 189% 6 111% and 102% 6 113% above baseline by 48 h. The liver signal was the most variable, likely reflecting different iron and fat content, and variable uptake and retention of iron oxide across the study population.
Measurements in muscle were variable across patients, but as expected, changes with contrast administration were comparatively small. All postcontrast increases in liver, renal cortex, muscle, and blood were significant (P < 0.005). By 48 h, changes in liver R 2 and R Ã 2 relative to precontrast were still significant (P < 0.005), as were renal cortex R 2 and blood R of change were seen on day 15 scans for all normal tissue. R 2 and R Ã 2 values on day 15 before contrast administration in liver, renal cortex, muscle, and blood were not significantly different than the precontrast values measured at screening, based on paired t-tests (P > 0.05).
Representative CT and T 2 -weighted MRI images acquired before and after ferumoxytol injection in a colorectal cancer patient are shown in Figures 3a-c ; the heterogeneity of the multiple liver lesions can be appreciated in the postcontrast image. Maps of DR 2 , DR Ã 2 , Q, and ADC are also shown for the same patient (Figs.  3d-g ); the core of the large central lesion is necrotic with high ADC. For quantitative analysis, we measured the offshoot of the lesion with relatively low ADC (0.98 Â 10 À3 mm 2 /s), as indicated on the DR 2 map. Some artifacts appear on the right side of the images due to local mis-registration of the liver across multiple breathholds.
Repeatability of VSI metrics in tumors could not be directly assessed given the lack of double-baseline measurements in our protocol. However, given that the treatment was not expected to affect normal tissues such as the renal cortex, comparisons between screening and day 15 data served as an approximation. The repeatability of DR 2 , DR Ã 2 , and Q in the renal cortex, as measured by the coefficient of variation (CV%) derived from the paired screening and day 15 scans from each subject, ranged from 12.3 to 14%, while the CV% for ADC was 4.9% (Fig. 4) ; these CV% values are consistent with those reported for other MRI-based vascular metrics, such as K trans (39) . Side-by-side comparisons of screening and day 15 results for both ADC and Q measurements paired by patient are also shown.
Plots of the time course of R 2 and R Ã 2 in individual lesions are shown in Figure 5 , grouped by lesion location. Postinjection, the mean increase in R 2 was 34% 6 16% (P < 0.005) which dropped to 29% 6 22% (P < 0.005) above baseline by 48 h; R Ã 2 increased by 182% 6 90% (P < 0.005) and returned to 72% 6 49% (P < 0.005) above baseline by 48 h. The persistent increase in R 2 at 48 h (indeed progressive increase in some lesions) contrasts to the near complete recovery of R 2 in blood and renal cortex. The persistent increases at 48 h may be due to accumulation of contrast agent due to extravasation, or uptake by macrophages within a lesion. While there was significant variability in baseline R 2 value between lesions, the relative change following ferumoxytol was quite consistent. The two lung lesions had much higher R Ã 2 values at baseline (Fig. 5b) , which may be indicative of hemorrhagic necrosis; however, overall, 
Clinical Data: Model-Generated Comparisons
As shown in Figure 7 , the correlation between ͱR Ã 2blood and the contrast agent blood concentration, calculated for each subject as the injected dose of Fe divided by the total blood volume estimated using the Nalder Method, was significant (r 2 ¼ 0.62; P < 0.02), indicating ͱR Ã 2blood is a reasonable surrogate for blood contrast agent concentration. DR 2 and DR Ã 2 measurements from parametric maps derived from registered images were compared with results generated from the simplified whole-lesion ROI for all target lesions. The correlation between the two approaches was very high (r 2 ¼ 0.98); the simplified approach yields very similar values compared with the image-based method, although at the cost of losing information on heterogeneity within the ROI. Similar findings were also seen for the derived vessel density-related parameter, Q.
Preclinical Comparison. Figure 9 shows representative maps (ADC, DR 2 , DR Ã 2 , and Q) from a xenograft tumor; the qualitative relationships between parameters are similar to those seen for the lesions in our patient cohort. Plots of DR 2 , DR Ã 2 , and Q are also shown for both mouse and human tumors. Differences in the relaxation rate changes between human and mouse measurements likely reflect methodological differences (field strength 1.5T versus 4.7T), different pulse sequences (multiecho versus incremented spinecho T 2 measurement), and manual tumor segmentation versus automated segmentation of viable xenograft tissue using a multispectral approach (8, 36, 37) . Variability in both DR 2 and DR Ã 2 was much higher across the human subjects, which may be expected given a Phase I population and lesion location heterogeneity in comparison to xenograft models. However, it is interesting to note that the variability in Q across the human subjects was more consistent with the mouse measures. Median tumor Q in mice was about twice the median Q in human tumors. This may reflect a true increased vessel density due to the subcutaneous nature of flank xenograft models, although results are also likely affected by better segmentation of mouse tumors compared with human tumors, and other methodological differences such as field strength and pulse sequence details.
The median relative VVF of the HM-7 flank xenograft tumors compared with quadriceps muscle in mice was 1.4, indicating a 40% increase in VVF in tumors compared with VVF in muscle. This is in the range of what might be expected given the VVF values reported in the literature for mouse muscle VVF [1.89% (40) ] and various xenograft tumor models [2.1%-6.6% (40) and 0.8%-3.24% (41, 42) ]. Assuming a total blood volume of 70 mL/ kg, the median relative VVF in mouse muscle compared with human muscle was estimated as (11.8 s À1 /5.7 s À1 )*(3 mg/kg Fe/6 mg/kg Fe) ¼ 1.0, indicating that measured muscle blood volumes are similar between species. The median relative VVF of tumors compared with muscle in humans was 4.9, indicating a higher relative blood volume in tumors compared with muscle in humans, as well as higher relative blood volumes in human tumors ($9%) compared with xenograft tumors.
DISCUSSION
While DCE-MRI is well-suited for therapies that target the VEGF pathway because of its sensitivity to alterations in vascular permeability, the development of therapies that induce structural changes unrelated to permeability would benefit from robust in vivo measures of microvascular structure. The clinical availability of an intravascular contrast agent with a relatively long halflife allows the expansion of available tools for the assessment of new oncologic therapies with a range of antiangiogenic mechanisms of action. The data in this study demonstrate the feasibility of evaluating tumor vasculature in metastatic lesions throughout the body using the USPIO agent ferumoxytol as an intravascular contrast agent and standard product pulse sequences on commercial MRI scanners. Operationally, there were minimal hurdles to including the use of ferumoxytol as part of the investigative study; most of the clinical sites already had general experience with ferumoxytol as a therapy for anemia in their oncology patients, and no additional IRB reviews were required.
We observed no adverse events related to ferumoxytol injection. Since the completion of our study, the US Food and Drug Administration strengthened its existing safety warning on the Feraheme label, reflecting continued postmarketing observations of severe adverse events. Most gadolinium contrast agents also carry "black box" warnings that highlight potential risks but do not account for possible benefits of using these agents, such as more accurate diagnosis and therapy selection. We believe that VSI using ferumoxytol will ultimately be shown to convey a similar benefit to patients that will outweigh the low risk of anaphylaxis. Nevertheless, the recent FDA warning underlines the need to closely monitor patients receiving ferumoxytol while in the magnet as well as afterward, and to ensure adequate acute care is available for any adverse events.
Overall, image quality was sufficient for analysis. Although artifacts due to patient motion were present in some scans, it did not preclude measurements in the tumors. At a minimum, a multiecho gradient echo sequence is needed for R Ã 2 measurement, which may not be available on some older scanners. The use of a bloodpool contrast agent allows for steady-state imaging with slower temporal and higher spatial resolution sequences. This is counterbalanced by the requirement of maintaining individual acquisitions within a reasonable breathholding duration and obtaining full coverage of target lesions(s) along with relevant normal tissue. These considerations tended to increase total acquisition times in the current protocol. While breath-holding minimized motion artifacts in the scans, spatial registration across multiple series is required to calculate VSI parameters, and this proved challenging in some cases where lesions were small or the diaphragm position changed markedly between individual breath-holds.
The necessity of breath-holding for scanning abdominal lesions also dictated the use of a turbo spin-echo sequence for estimating R 2 . Furthermore, both short and long TE images must be acquired in the same breathhold, because acquiring them in sequential breath-holds results in noisy R 2 and DR 2 estimates due to even small spatial registration errors. Although we optimized the TSE parameters as far as possible to achieve reasonable coverage over a small number of breath-holds, this still resulted in a 7-to 10-ms echo spacing. A short echo spacing in the TSE echo train inevitably results in reduced sensitivity to diffusion driven spin dephasing within the magnetic susceptibility gradients around microvessels, which is a key component of the VSI model (31) . As a result, we likely underestimate DR 2 changes due to ferumoxytol injection. One solution to this problem is the use of spin-echo EPI sequences. Multishot T 2 -weighted echo planar imaging is available on most modern scanners, and this generates a rapid long-TE spin-echo image; however, these sequences typically do not yet allow generation of both short and long TE images required to calculate R 2 within a single breathhold. Another challenge with EPI is the narrow phaseencode bandwidth, which can result in significant phase-encode direction blurring after the injection of susceptibility contrast agents, which is problematic for small structures. Nevertheless the use of more efficient novel EPI sequences for measuring changes in T 2 and T Ã 2 simultaneously (13-17) may be ideal for making VSI measurements with USPIOs, if used in multishot rather than single-shot mode.
Another limitation of our methodology is the relatively noisy measurement of R Ã 2 in whole blood after ferumoxytol injection. Even with dilution of the injection volume with saline, R Ã 2 was difficult to measure in whole blood because the TE values used in our gradient echo sequence were optimized for tumor measurements. In future, the inclusion of an additional gradient echo acquisition with much shorter TE values would allow more accurate estimates of tumor blood volume by better characterizing the magnetic susceptibility shift in whole blood. Our intention in this study was to evaluate the feasibility of clinical VSI using currently available pulse sequences in the challenging setting of imaging abdominal tumors. As multiecho multishot EPI based sequences are more widely implemented on clinical scanners, the accuracy of these VSI metrics in organs outside of the head will likely improve.
The problem of spatial misregistration errors when calculating VSI metrics from multiple input images and multiple breath-holds can be addressed by the calculation of median tumor values from the individual (pre-, postcontrast R 2 , and R Ã 2 ), which can then be used to calculate a single value for average tumor Q or blood volume. This approach produced values in excellent agreement with median values measured from registered Q and DR Ã 2 maps, suggesting it is sufficient for quantifying average tumor properties. In addition, our approach to ROI definition tended to define fairly homogeneousappearing tumor regions by using diffusion scans to avoid regions of obvious necrosis or hemorrhage.
These data were consistent with the theory of microvascular imaging and experimental findings of previous investigators (4). Although our protocol used a fixed mg/ kg contrast agent dose, we observed linear relationships between R Ã 2tissue and contrast agent concentration in each subject, either calculated from total blood volume estimates or ͱDR Ã 2 measured in blood. We also observed a linear relationship between DR 2 and DR Ã 2 in tumor and normal tissue, and most importantly, found that Q was relatively independent of DR Ã 2 and, therefore, contrast agent concentration. These results provide further support that Q is a promising biomarker, even in the heterogeneous setting of Phase I clinical trials of antiangiogenic therapies enrolling patients with diverse solid tumors.
The high level of ferumoxytol accumulation in the liver did not prevent the measurement of VSI metrics in hepatic metastases. Close inspection of the images revealed that the boundaries of liver lesions were well defined on scans both immediately postinjection and 48 h postinjection. On the 48 h image, markedly elevated relaxation rates were still present in tumors and liver, while blood and renal cortex values returned closer to baseline. Based on the $15 h plasma half-life of ferumoxytol in humans, approximately 10% of the original blood contrast agent concentration should remain after 48 h; accordingly, measurements of R Ã 2 and R 2 were slightly above baseline values in the blood pool and renal cortex at that timepoint. Sustained elevation of R Ã 2 and R 2 in liver at 48 h may be due to extravasation of the contrast agent and uptake by Kupffer cells. In tumors, R Ã 2 remained above baseline at 48 h, although below immediate postcontrast levels, while R 2 at 48 h was similar to the immediate postcontrast value and in some cases increased further. This is likely due to delayed leakage of ferumoxytol into the tumor extravascular space, which likely has much larger microvascular (R 2 ) than macrovascular (R Ã 2 ) relaxation effects. In addition, regional R 2 elevation in experimental breast tumor xenografts at 24 h post-ferumoxytol injection has been attributed to uptake by tumor-associated macrophages (43) , which may explain some of the progressive increase in R 2 seen in several tumors. It is possible that inclusion of the T1 measurements in tumor core and periphery may yield additional insight into whether delayed uptake of ferumoxytol is due to slow vascular extravasation or uptake into tumor associated macrophages, however, this issue is beyond the scope of the current study.
A limitation of this study was the lack of doublebaseline measurements to determine repeatability of these metrics in a clinical trial setting. However, it is encouraging to note that measures made in the renal cortex at screening and day 15 were consistent across subjects, with CV% less than 15%. Measurements in lesions at day 15 were not reported, as there were no clear trends in the small group of patients studied, some of whom had rapidly progressing disease with marked tumor size changes seen within a 2-week window.
While we do not have invasive measurements of tumor vessel density in these patients, previous preclinical studies have shown good agreement between MRIderived metrics and microvessel density measured by microCT (8) . Comparisons between clinical and preclinical data in this study show that estimates of Q are similar, although potentially slightly lower in human lesions compared with the xenograft models, while the variability of Q measurements are similar overall. Relative VVF measured in muscle was similar in mouse and humans, while relative blood volumes were approximately 3.5 times higher in human tumors compared with HM-7 xenograft tumors. Although we were not able to calculate absolute VVF values, relative values may still be useful, particularly when evaluating changes in VVF after treatment. Therefore, both relative VVF and Q may be viable markers of effect when studying anti-angiogenic therapies. More quantitative estimates of tumor microvessel density and vessel caliber are possible but require measurement of tumor diffusion coefficient and magnetic susceptibility shift (15, 44) . While we did measure ADC, an assessment of the blood susceptibility shift would require a more accurate blood DR Ã 2 measurement from a large vessel. Moreover, calculation of such metrics would be more valuable in future clinical studies that include tumor biopsies, allowing validation of these in vivo VSI metrics against invasive measurements of tumor vasculature.
CONCLUSIONS
Unlike DCE-MRI, the VSI approach does not rely on contrast agent extravasation or high temporal resolution imaging and may prove valuable for assessing novel antiangiogenic therapies that may not affect vascular permeability. Clinical VSI is feasible in a multicenter study of patients with lesions outside the brain, using standard MRI techniques and ferumoxytol as a contrast agent. Iron oxide contrast agent accumulation in the liver does not preclude measurement of VSI parameters in liver metastases. We observed no adverse side effects of repetitive ferumoxytol injection at 3 mg Fe/kg intravenous doses. A repeatability study is needed to establish test-retest variability, which in turn may be used to determine treatment changes in future trials of anti-angiogenic therapies.
